Kestine Lyo (Ebastine)

Ebastine, the active ingredient in Kestine Lyo, is a second‑generation H1 antihistamine presented as an oral tablet for systemic use. It is indicated for the relief of symptoms associated with allergic rhinitis and chronic urticaria in adults and adolescents. It provides effective symptom control with a favorable safety profile, minimizing sedation compared with first‑generation antihistamines.

GNH USA supplies Kestine Lyo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements across multiple markets.

Ebastine is a second‑generation H1 antihistamine that acts on histamine‑mediated allergic pathways.

Allergic rhinitis: reduces nasal congestion, itching, sneezing, and rhinorrhea. Chronic urticaria: alleviates wheals and itching associated with persistent hives. Seasonal allergic rhinitis: provides symptom control during pollen exposure. Perennial allergic rhinitis: offers continuous relief of year‑round nasal allergy symptoms.

Ebastine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Dry mouth: occasional sensation of throat dryness. - Drowsiness: rare, non‑sedating profile but occasional sleepiness. - Nausea: mild stomach upset.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Stevens‑Johnson syndrome: rare skin disorder with blistering. - Hepatic enzyme elevation: possible liver function changes, monitor if symptomatic.

Before prescribing Kestine Lyo, consider the following precautions. - Assess liver function: monitor hepatic enzymes in patients with known liver disease. - Adjust for renal impairment: use caution in severe renal dysfunction and consider dose modification. - Use in elderly with care: observe for increased sedation or dizziness. - Avoid concomitant antihistamines: combined use may increase anticholinergic load. - Do not exceed recommended duration: prolonged use should be reviewed by a physician. - Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Potential drug interactions should be evaluated prior to therapy.

Major Interactions (Avoid): - Ketoconazole: strong CYP3A4 inhibition may raise ebastine plasma levels. - Erythromycin: macrolide antibiotic that can increase ebastine exposure. - Ritonavir: potent CYP3A4 inhibitor leading to potential toxicity.

Moderate Interactions (Monitor Closely):\n- Alcohol: may enhance drowsiness. - CNS depressants: additive sedation possible.